The purpose of this study is to investigate the effect of co-administration with erythromycin on the time course of PH-797804 concentration in the blood following dosing by oral immediate release tablet formulation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
Tablet, 6mg, single
PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
Pfizer Investigational Site
Singapore, Singapore, Singapore
Maximum Observed Plasma Concentration (Cmax)
Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144,168,192,216,240 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144,168,192,216,240 hours post-dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144,168,192,216,240 hours post-dose
Plasma Decay Half-Life (t1/2)
Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144,168,192,216,240 hours post-dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144,168,192,216,240 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.